Production and Clinical Evaluation of Norwalk GI.1 Virus Lot 001-09NV in Norovirus Vaccine Development by Mateo, R. et al.
M A J O R  A R T I C L E
Production and Clinical Evaluation of Norwalk GI.1 Virus Lot 001-09NV in Norovirus Vaccine Development • jid 2020:221 (15 March) • 919
The Journal of Infectious Diseases
Received 12 September 2019; editorial decision 9 October 2019; accepted 12 October 2019; 
published online October 20, 2019.
Correspondence: Roberto Mateo, PhD, Vaxart, Inc., 385 Oyster Point Blvd., Suite 9A, South 
San Francisco, CA 94080 (rmateo@vaxart.com).
aR. M. and L. C. L. contributed equally to this work.
The Journal of Infectious Diseases®  2020;221:919–26
© The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases 
Society of America. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution 
License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, 
distribution, and reproduction in any medium, provided the original work is properly cited.
DOI: 10.1093/infdis/jiz540
Production and Clinical Evaluation of Norwalk GI.1 Virus 
Lot 001-09NV in Norovirus Vaccine Development
Roberto Mateo,1,a Lisa C. Lindesmith,2,a Shaily J. Garg,1 Keith Gottlieb,1 Karen Lin,1 Sara Said,1 Juan S. Leon,3 Amy C. Sims,2 David J. Weber,4  
Ralph S. Baric,2 Sean N. Tucker,1 and David N. Taylor1
1Vaxart, Inc., South San Francisco, California, USA, 2Department of Epidemiology, University of North Carolina, Chapel Hill, North Carolina, USA, 3Hubert Department of Global Health, Rollins 
School of Public Health, Emory University, Atlanta, Georgia, USA, 4Division of Infectious Diseases, University of North Carolina, Chapel Hill, North Carolina, USA
Background. Human noroviruses (HuNoV) are the leading cause of gastroenteritis. No vaccine is currently available to prevent 
norovirus illness or infection. Safe, infectious challenge strains are needed to assess vaccine efficacy in the controlled human infec-
tion model (CHIM).
Methods. A stock of HuNoV strain Norwalk virus ([NV] GI.1) was prepared. Healthy, genetically susceptible adults were inocu-
lated with NV Lot 001-09NV and monitored for infection, gastroenteritis symptoms, and immune responses.
Results. Lot 001-09NV induced gastroenteritis in 9 (56%) and infection in 11 (69%) of 16 genetically susceptible subjects. All 
infected subjects developed strong immune responses to GI.1 with a 30-fold (geometric mean titer) increase in blocking titers (BT50) 
and a 161-fold increase in GI.1-specific immunoglobulin (Ig)G titers when compared with baseline. GI.1-specific cellular responses 
in peripheral blood were observed 9 days postchallenge with an average of 3253 IgA and 1227 IgG antibody-secreting cells per mil-
lion peripheral blood mononuclear cells.
Conclusions. GI.1 Lot 001-09NV appears to be similar in virulence to previous passages of NV strain 8fIIa. The safety profile, 
attack rate, and duration of illness make GI.1 Lot 001-09NV a useful challenge strain for future vaccine studies aimed at establishing 
immune correlates.
Keywords. antibody-secreting cells; blockade antibody; controlled human infection model; human challenge study; human 
norovirus.
Diarrhea is a leading cause of morbidity and mortality in 
children under 5 years of age [1]. Human norovirus (HuNoV) 
is the leading cause of acute gastroenteritis, causing an esti-
mated 200 000 deaths per year, mostly in young children and 
older adults [2]. This high disease burden is facilitated by exten-
sive antigenic diversity between the >30 genotypes of HuNoV 
coupled with antigenic drift within the predominant genotype, 
GII.4 [3]. Antigenic drift among GII.4 strains has resulted in 
serial pandemic waves of disease in 2- to 7-year cycles over the 
past 3 decades [3, 4]. Strains outside the GII.4 genotype are as-
sociated with endemic disease and are primarily detected in 
young children [5]. Substantial antigenic diversity and limited 
cross-reactivity between genotypes have hampered the develop-
ment of HuNoV vaccines. With the successful implementation 
of the rotavirus vaccine program in children, vaccines to 
HuNoV are now a high priority [6].
Most HuNoV disease is caused by strains within 2 genogroups 
(G), GI and GII. Genetic susceptibility to HuNoV infection is 
mediated by enzymes of the ABO, Lewis, and secretor histoblood 
group antigen (HBGA) pathways [7]. Human norovirus-HBGA 
interaction is genotype specific. Cross-genogroup immunity is 
limited among infected children [5] and vaccinated mice [8], 
whereas vaccination in adults, in the short-term, boosts anti-
bodies able to broadly block binding of strains to HBGAs in 
a surrogate neutralization assay [9]. These blockade antibodies 
correlate with protection from infection and are a leading 
metric for vaccine immunogenicity studies [10, 11]. Other cor-
relates of protection include mucosal immunoglobulin (Ig)A, 
serum IgA, and memory IgG B cells [12]. Individuals who do 
not have a functional secretor enzyme are genetically resistant 
to GI.1 infection [13, 14], yet GII.2 infection is independent of 
secretor type [15]. How genetic susceptibility and the immunity 
it shapes impacts vaccine response is not yet fully understood.
Controlled human infection models (CHIM) are being used 
with increasing frequency to evaluate vaccine candidates, thus 
methods to isolate and purify noncultivatable/recalcitrant vir-
uses, such as HuNoV, are needed. This study was designed to 
develop a methodological pipeline to manufacture high-quality 
stocks of HuNoV for application in CHIM to elucidate the 
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mechanisms of HuNoV susceptibility, immunity, and vaccine 
efficacy. After this pipeline, we prepared a stock of Norwalk 
virus (NV), traced its stability and sterility over a 10-year 
period, and demonstrated infectivity in humans of GI.1 Lot 
001-09NV (NV). The development protocol yielded enough
virus to generate robust immune responses in healthy adults.
A  similar purification approach could be applied to develop
standardized, high-quality infectious virus stocks to other en-
teric viruses lacking high-throughput cell culture systems.
METHODS
Regulatory and Ethics Statement
Protocols for the source fecal sample collections and proc-
essing for challenge virus were approved by the Institutional 
Review Board (IRB) at the University of North Carolina 
Chapel Hill (no. GCRC-2355) and awarded Investigational 
New Drug Application (IND) 14697. The clinical trial was 
conducted by West Coast Clinical Trials ([WCCT] Costa Mesa, 
CA) under IND 18352. The clinical protocol was reviewed and 
approved by Aspire IRB (Santee, CA). Written informed con-
sent was obtained from all subjects before any study related 
assessments. The study was registered at clinicaltrials.gov 
(NCT03721549).
Preparation of Challenge Strain Virus Stocks
The challenge virus stock was prepared from a healthy donor 
challenged with GI.1 NV in 1999 [13] at the University of 
North Carolina Chapel Hill General Clinical Research Center 
(Supplementary Tables 1  and 2).
Thirty-two grams of GI.1 (1.8  ×  108 genome copies [GC]/
mL) stool sample were diluted 1/5 in sterile water, vortexed for 
5 minutes, centrifuged for 10 minutes at 9400 relative centrif-
ugal force (RCF), the supernatant was removed, and the pellet 
was resuspended in sterile water in a washing process repeated 
4 more times. The washed supernatants were pooled and centri-
fuged for an additional 60 minutes at 9400 RCF (Pre-Filtrate), 
followed by 0.22-µm filtration (Filtrate 1), and a second 0.22-µm 
filtration (purified bulk harvest [PBH]). Purified bulk harvest 
was stored at 4°C, whereas the virus titer (GC) was determined 
by quantitative reverse-transcription polymerase chain reaction 
(qRT-PCR) at Emory University [16]. The room was cleared of 
supplies, disinfected, and environmental monitoring repeated. 
A portion of the PBH was then diluted to the desired GC per mL 
(0.5–1.2 × 106) and aliquoted into ~500 1-mL doses as the final fill 
and stored at less than −60°C. The remaining PBH was aliquoted 
and stored at less than −60°C for future packaging of sublots. 
Approximately, 45% (G1.1) and 72% (GII.2) of the total PBH 
was needed to complete the safety testing protocols described in 
Supplementary Table 2. The PBH and final fill were sterile, and 
no adventitious viruses were detected in virus-specific assays, 
MRC-5, VERO or HeLa cell lines, embryonic Hen eggs, or adult 
and newborn mice (Supplementary Table 2).
Study Design Using the Manufactured Challenge Strain Virus Stocks
Healthy men and women between 18 and 49  years of age 
were recruited. A  total of 40 secretor-positive, blood group 
O or A subjects were screened to identify 16 eligible subjects. 
Initially, 8 eligible subjects were assigned to the low-dose chal-
lenge (3.6 × 105 GC of NV) and admitted to a private room at 
the inpatient challenge facility (WCCT) on the day before chal-
lenge. On the day of challenge, the 8 study subjects in this co-
hort were given 100  mL bicarbonate buffer (1.3% NaHCO3) 
solution to neutralize stomach acid after an overnight fast. 
Approximately 1 minute later, the subjects ingested the NV in-
oculum suspended in 100 mL distilled water.
After viral challenge, study subjects were assessed for symp-
toms and signs of gastroenteritis every 2 hours while awake for 
the first 48 hours and then every 8 hours on Day 3 through the 
5-day inpatient period (+1 day if still symptomatic). All fecal
and emesis samples were collected and were weighed, graded
(fecal samples), and processed for NV infection using qRT-
PCR [17, 18]. Saliva and blood samples were also collected at
prespecified timepoints. Subjects were assessed by the nursing
staff for anticipated subjective symptoms of NV illness (diar-
rhea, vomiting, headache, nausea, fever, abdominal cramps or
pain, abdominal burgling or bloating and myalgia), as well as
unsolicited adverse events (AEs).
Once all subjects in Cohort 1 (low dose) had completed their 
Day 14 visits, the second group of 8 subjects were challenged 
with a higher dose of approximately 1 × 106 GC (high dose) and 
followed as described above.
Illness Definitions
Acute gastroenteritis (AGE) was defined according to the cri-
teria of Bernstein [19] as follows: (1) diarrhea (≥3 loose or 
liquid stools or >400 grams of loose or liquid stools produced 
in any 24-hour period) or (2) vomiting (≥2 vomiting episodes 
in any 24-hour period), or (3) 1 vomiting episode plus any 
loose or liquid stool in any 24-hour period, or (4) 1 vomiting 
episode plus at least 2 of the following 5 events: nausea, oral 
temperature ≥37.6°C, abdominal cramps or pain, abdominal 
gurgling or bloating, or myalgia in any 24-hour period during 
the postchallenge sequestration period. Norwalk virus infection 
was confirmed by fecal virus excretion detected by qRT-PCR on 
any day postchallenge. Norwalk virus AGE met both criteria. 
The modified Vesikari (17 point) scale was also used to grade 
the severity of illness [20].
Secretor Assay
Saliva specimens were evaluated for H type-1 antigens secretor 
status by enzyme-linked immunosorbent assay (ELISA) at the 
Cincinnati Children’s Hospital Medical Center (CCHMC) [21, 22].
Norwalk Virus Detection
Fecal samples were evaluated for the presence of NV by qRT-
PCR assay for the viral genome at CCHMC.
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Statistical Analysis
Frequency of NV disease and infection were compared between 
the low- and high-dose groups by means of Fisher’s exact test. 
The dates of onset and resolution of AGE were determined by 
reviewing the subject’s clinical onset and duration of diarrheal 
stool (grade 3 or greater).
Blockade Antibody Assay (BT50)
Serum samples were obtained at baseline (Day 1) prechallenge 
and 28 days postchallenge. In brief, biotinylated Leb (Glycotech) 
at 2.5  µg/mL was used to coat Neutravidin-coated plates 
(Thermo Fisher Scientific). Two-fold dilutions of serum with 
GI.1 virus-like particle (VLP) were incubated at 37°C for 1 
hour. The mixture of VLP and serum samples was added to 
HBGA-coated plates and incubated at 4°C for 2 hours. After 
washing, rabbit anti-GI.1 VLP polyclonal antisera (custom 
made by Thermo Fisher Scientific) was added and incubated 
at 4oC for 1 hour. Goat antirabbit IgG(H+L)-horseradish per-
oxidase (HRP) (A120-101P; Bethyl Laboratories) was used to 
detect bound rabbit antibody (4°C for 1 hour). With the starting 
dilution of 1:25, a negative value was set equal to 12.5 [11, 23].
Peripheral Blood Mononuclear Cell Isolation and Cryopreservation
Peripheral blood mononuclear cells (PBMCs) were obtained 
before and at days 6 and 9 after challenge for the detection of 
IgA and IgG antibody-secreting cells (ASCs). Blood was col-
lected in K2 EDTA Vacutainer tubes (BD), and PBMCs were 
isolated the same day using Lymphoprep tubes (Cosmo Bio 
USA, Carlsbad). The PBMCs were frozen and thawed using 
serum-free reagents according to the manufacturer’s instruc-
tions (Cellular Technology Ltd).
Antibody-Secreting Cells and Enzyme-Linked Immunosorbent Assay 
Serum Antibodies
Antibody-secreting cells were measured using cryopreserved 
PBMCs and enzyme-linked immunosorbent (ELISpot) kits for 
IgG and IgA secreting B cells according to manufacturer’s in-
structions (Mabtech). Cells were cultured in triplicate with anti-
IgG- or IgA-coated wells in CTL-Test Medium overnight. GI.1 
VLPs made in HEK293 cells (AscentGene, Gaithersburg, MD) 
were biotinylated and quantitated using a biotinylation kit and 
BCA kit (Pierce). Spots were developed using biotinylated GI.1 
VLP and streptavidin-HRP and counted at ZellNet Consulting 
Inc. (Fort Lee, NJ).
Immunoglobulin G Titer Determination
Serum IgG titers were determined using a MESO QuickPlex SQ 
120 instrument (Rockville, MD) following the manufacturer’s 
instructions and reagents. In brief, Meso Scale Discovery 
(MSD) Gold Streptavidin plates were blocked with 150 µl of 3% 
blocker B blocking solution made in phosphate-buffered tween 
(PBST) for 30 minutes while shaking. Plates were then washed 3 
times with PBST and coated with G1.1 VLP-biotin at 0.1 µg/mL 
in 1% blocker B and incubated for 1 hour while shaking. Serum 
sample dilutions were made starting at 1:100 in 1% blocker B 
in PBST and diluted 1:4 down the plate. After washing, serum 
sample dilutions were added to the plates and incubated for 
2 hours while shaking at room temperature. Plates were then 
washed 3 times with PBST. A  total of 1  µg/mL SULFO-TAG 
anti-IgG antibodies, diluted in 1% blocker B, was then added to 
the plates and incubated for 1 hour shaking at room tempera-
ture. Plates were then washed and read after addition of 2× read 
buffer diluted in H2O.
RESULTS
Virus Lot Purification and Isolation
The milestones for development of the stool-derived virus stock 
001-09NV is outlined in Supplementary Figure 1. A  single
stool sample from 1 GI.1-infected [13] donor was subjected to
5 rounds of sterile water dilution and centrifugation, and the
supernatants were pooled (Pre-Filtrate) before being sterile fil-
tered (Filtrate 1) twice to generate the PBH. Aliquots before the
filtration step contained bacteria and fungi. The postfiltration
samples were free of bacteria and fungi and all other tested
pathogens (Supplementary Table 2). A portion of the PBH was
further diluted and vialed in 1-mL doses, recorded as Lot 001-
09NV (GI.1). The remainder of the PBH was stored in bulk for
future sublots. As expected, the stool-derived product contained 
endotoxin, although at levels 3- to 8-fold less than GI.1 8FIIb,
a HuNoV strain used in previous CHIM [13] (Supplementary
Table 2). The virus stock was stable, sterile, and infectious in
storage as tested over the past 10 years (Table 1). A request for
use of 001-09NV virus stock in CHIM was submitted and ap-
proved to the US Food and Drug Administration (FDA), under
an IND (14697).
Clinical Outcome
All subjects enrolled in the challenge study were healthy men 
and women 18–49  years old that were secretor-positive and 
blood group O or A. The mean age of the subjects was 33 years 
old in the low-dose group and 40  years old in the high-dose 
group (Table 2). No unexpected/unsolicited AEs or serious AEs 
were reported. Unexpected/unsolicited AEs exclude gastroen-
teritis symptoms because gastroenteritis is expected after inges-
tion of live norovirus. Expected/solicited AEs included nausea, 
diarrhea, vomiting, abdominal pain, fever, muscle aches, head-
ache, and chills. In previous studies, norovirus challenge strains 
have been safely administered [19, 20, 24].
In the low-dose group, 5 of 8 subjects (63%) met the criteria 
for AGE and were also positive for NV by qRT-PCR (Table 3). 
The other 3 subjects in the cohort were well and NV negative. 
In the high-dose group, 6 of 8 (75%) were NV positive; 4 met 
the AGE criteria, and 2 others had milder diarrhea that did not 
meet the definition of AGE. One subject was well and NV neg-
ative, and another subject had diarrhea and was negative for 
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both NV GI.1, GII.4, and other enteric pathogens (data not 
shown). Overall, there were no statistical differences in out-
come among treatment groups. Among those subjects who had 
AGE and were NV positive, the illness appeared more severe in 
the high-dose group as measured by diarrheal stool output and 
vomiting. The onset of illness was shorter, and the duration of 
illness was longer in the high-dose group. The Vesikari score 
was also higher in the high-dose group compared with the low-
dose group (6.3 vs 4.8), and the mean maximum body temper-
ature was also slightly higher in the high-dose group (Table 4). 
None of the differences between dose groups was statistically 
significant. The symptoms recorded among the 9 subjects with 
AGE and who were NV positive were in general mild to mod-
erate in nature (data not shown).
Norwalk virus shedding was highly correlated with diar-
rheal stool (grade 3 or greater). In the low-dose group, shed-
ding ranged from 105 to 1010 GC/gram of stool. Virus was also 
detected in emesis in 1 of 2 subjects. Similar results were ob-
served in the high-dose group. The level of viral shedding did 
not correlate with the amount of diarrheal stool. Norwalk virus 
was detected in 3 of 16 subjects on day 9.
Immunological Responses
Serological and cellular assays were used to evaluate the immu-
nological responses to norovirus challenge. Subjects that were 
positive for NV shedding were further subclassified into posi-
tive or negative for AGE (Table 5), and their immune responses 
were compared.
BT50 Blockade Assays
Blockade assays were used as the primary endpoint to test for 
subject seroconversion after viral challenge. Subjects with a 
geometric mean fold rise (GMFR) >4 from baseline titer were 
considered successfully seroconverted for blockade antibody. 
On day 28, all subjects that were positive for norovirus had an 
average BT50 titer of 1205, which represented a GMFR >30-fold 
from day 1 with a 100% seroconversion rate (11 of 11). It is re-
markable that, within the AGE group, 4 of 16 subjects (25%) and 
2 of 16 subjects (12.5%) had a 32- and a 64-fold increase in BT50 
titer by day 28, respectively. In contrast, none of the subjects 
negative for NV seroconverted for blockade antibody by day 28, 
only showing a 1.3-fold BT50 titer increase from day 1.
Serum Immunoglobulin G Titer Determination
GI.1-specific IgG responses closely matched the trends ob-
served in BT50 assays. Norwalk virus-positive subjects, with a 
range of titers between 204 800 and 3 276 800 on day 28, had 
an average 136-fold GMFR from baseline in ELISA titers, as 
Table 1. Virus Stock Stability and Sterility Over Timea
001-09NV
Year GC/mL Sterility Endotoxin EU/mL
2009 Manufacture 5 × 105 Negative for growth 235
2011 IND 6 × 105 Negative for growth N/D
2018 001-09NV Trial 3.6 × 105 Negative for growth 165
2019 001-09NV Trial 1.4 × 105 Negative for growth 155
Abbreviations: EU, endotoxin units; GC, genome copies; IND, Investigational New Drug; N/D, not determined.
aHuman noroviruses final fill lots were tested for virus stability (mean GC per mL), sterility, and endotoxin at manufacture, US Food and Drug Administration IND Application submission, 
initiation of studies, and annually during ongoing studies. Testing was not performed during years of nonhuman use.
Table 2. Demographic Characteristics by Dose Cohort
Dose Cohorta
Low High All
Baseline demographics n = 8 n = 8 n = 16
Mean age (years) 32.5 39.9 36.3
Gender
Female 3 (37) 4 (50) 7 (44)
Male 5 (63) 4 (50) 9 (56)
Ethnicity
Hispanic 2 (25) 4 (50) 6 (38)
Not Hispanic 6 (75) 4 (50) 10 (63)
Race
White 4 (50) 5 (63) 9 (56)
Black 4 (50) 2 (25) 6 (38)
Asian 0 1 (13) 1 (6)
Body mass index (mean) 25.7 27.1 26.4
Blood Type
A 3 (37) 5 (63) 8 (50)
O 5 (63) 3 (37) 8 (50)
Secretor status positive 8 (100) 8 (100) 16 (100)
Table 3. Summary of the Correlation Between Acute Gastroenteritis and 
NV Positivity by Cohort
Dose Cohort
Category Low High All
Illness Infection n = 8 n = 8 n = 16
AGE NV+ 5 (62.5) 4 (50) 9 (56.3)
Well NV+ 0 2 (25) 2 (12.5)
AGE NV− 0 1 (12.5) 1 (6.3)
Well NV− 3 (37.5) 1 (12.5) 4 (25)
Abbreviations: AGE, acute gastroenteritis; NV, Norwalk virus.
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measured by MSD. Within the AGE group, 4 of 16 subjects 
(25%) and 1 of 16 subjects (6.25%) had a 256-fold and a 1024-
fold increase in serum IgG titer by day 28, respectively. Only 
1 subject that did not meet the criteria to be considered posi-
tive for AGE responded with a 64-fold increase in ELISA titers 
by day 28. However, none of the subjects who were negative 
for AGE seroconverted. As expected, there was a high posi-
tive correlation between serum BT50 and NV-VLP IgG ELISA 
titers both at baseline (Pearson r = 0.91) and at day 28 (Pearson 
r = 0.88).
Antibody-Secreting Cell Assays
Antibody-secreting cell responses (IgA and IgG) were measured 
in all subjects at 3 different timepoints: day 1 (prechallenge), day 
6 and day 9 (5 and 8 days after challenge, respectively). Counts 
were low/negligible on days 1 and 6 but rose to high ASC 
numbers on day 9 in NV-positive subjects (Table 5). On average, 
NV-positive subjects with AGE had 3253 IgA ASC and 1227 IgG 
ASC spot counts per 1 × 106 PBMCs on day 9, showing a bias to-
ward IgA versus IgG. It is remarkable that 8 of 16 subjects (50%) 
had IgA ASC spot counts ≥2000 on day 9.  Immunoglobulin 
A ASC counts were approximately 50% higher among subjects 
who were ill compared with the 2 subjects who were asympto-
matic (Table 5). As expected, subjects that were negative for NV 
had negligible ASC spot counts on any day.
All 11 NV-positive subjects showed strong serum and ASC 
responses, whereas the 5 subjects who were NV negative had 
no detectable immune responses (Table 5). Three of 16 subjects 
(19%) had baseline BT50 GI.1 titers of ≥1:200 and showed no 
NV-related symptoms, supporting previous observations 
indicating that blockade antibody titer correlates with protec-
tion from symptomatic norovirus infection [10, 11]. Two other 
Table 4. Characterization of Diarrhea in Subjects With Acute Gastroenteritis and NV Positivity by Cohort (by Mean)
Characteristic Low Dose High Dose All Subjects
Number of subjects 5 4 9
No. diarrheal stools 3.4 8.3 5.6
Total wt. (g) 599 880 723.7
No. vomiting episodes 1.5 2.7 2.2
Highest temperature (°C) 37.3 37.5 37.4
Time to onset (h) 52.5 36.9 45.6
Duration diarrhea (h) 10 20.7 14.7
Vesikari score 4.8 6.3 5.4
Abbreviations: h, hours; NV, Norwalk virus; wt, weight.
Table 5. Cellular and Serological Immune Responses Analyzed by Clinical Outcome
All NV+ NV+/AGE NV+/Well NV Negativea
No. of Subjects n = 11 n = 9 n = 2 n = 5
BT50 (GMT)
Day 1 39 35 59 100
Day 28 1205 1048 2263 130
GM fold increase 31 30 38 1.3
≥4-fold increase 11 9 2 0
Serum IgG (GMT)
Day 1 3200 2743 6400 18 102
Day 28 436 241 442 392 409 600 18 102
GM fold increase 136 161 64 0.9
≥4-fold increase 11 9 2 0
IgA ASC (Avg)
Day 1 1 1 1 1
Day 6 4 4 2 3
Day 9 3011 3253 1920 6
IgG ASC (Avg)
Day 1 0 0 0 0
Day 6 1 2 0 1
Day 9 1288 1227 1564 2
Abbreviations: ASC, antibody-secreting cells; Avg, average; GM, geometric mean; GMT, GM titer; Ig, immunoglobulin; NV, Norwalk virus; 
aOne subject did not return on day 28 and was excluded from BT50 and IgG enzyme-linked immunosorbent assay day 1 baseline analysis.
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NV-negative, asymptomatic subjects had BT50 titers of 25 and 
50, respectively, suggesting additional, as yet undefined, mech-
anisms of norovirus illness protection.
DISCUSSION
Vaccine efficacy studies using a human challenge design require 
large quantities of well characterized virus stocks that meet FDA 
sterility and purity requirements for use in humans. Using a 
sample collected during our previous HuNoV infectivity study, 
we prepared virus stock for the genogroup I protype strain, GI.1 
NV [13]. These strains are good HuNoV vaccine testing candi-
dates because they circulate in the population and the environ-
ment but are typically not associated with pandemic levels of 
disease [3, 18]. Unlike the pandemic GII.4 HuNoV strains [25], 
the results of challenge studies with GI.1 and GII.2 are less likely 
to be complicated by high levels of either community-acquired 
infections or herd immunity within the test population, while 
providing key information on strain susceptibility and vaccine-
induced breadth of immunity.
This study describes the infectivity of the GI.1 NV Lot 
001-09NV in humans, initially developed as a tool to better
characterize and standardize immune responses generated
by CHIM infections. The data presented here support that
001-09NV infectivity has been maintained over time after
extensive passaging in healthy human volunteers and, more
importantly, is similar to that of its parent strain, 8FIIa, pre-
viously tested in several trials [13, 26]. In the current study,
all subjects that were positive for stool NV had a strong sero-
logical and cellular immune response to NV. Specifically, sub-
stantial increases in serum antibody responses were observed,
with a GMFR from baseline of 31 in BT50 and 136 in IgG titers
measured on day 28 postchallenge. Previous studies with
Vaxart’s oral norovirus vaccine have shown that such immuni-
zation elicited a cellular response that was skewed toward IgA
with an average IgA ASC spot count of 561 per 1 × 106 PBMCs 
(0–1600) among subjects who received the highest dose
at day 7 postimmunization [23]. In the present study, chal-
lenged subjects also showed a stronger cellular IgA response,
although with a higher variability in magnitude, and an av-
erage IgA ASC spot count of over 2000 (range, 0 to 6800) on
day 9 postchallenge, suggesting that responses to NV infection 
are considerably higher than those elicited by vaccination. For
varicella-zoster virus (VZV), the antibody responses after im-
munization with the VZV vaccine (live-attenuated), while still 
protective, have been estimated >10-fold lower than those
elicited after natural infection [27]. In our study, all 11 subjects 
that were infected with NV and ill had a 4-fold increase in
BT50 titers from baseline by day 28, consistent with previous
challenge studies with other GI.1 inoculums [11]. The magni-
tude of the BT50 titers on day 28 was similar to that reported
in some previous challenge studies [11, 28]. Overall, our data
show that the seroresponses observed after NV challenge are
comparable to those observed in previous controlled human 
infection studies with similar strains of genogroup GI.1 [20].
The present study provides a robust platform and a pipeline 
for studies with other noncultivable enteric viruses of impor-
tance to human and veterinary health such as sapovirus, re-
ovirus, or adenovirus. Our approach furthers other vaccine 
studies because it opens the possibility to use Lot 001-09NV 
for studying protective immunity markers against norovirus in-
fections. Virus neutralization assays are not available for NV. 
Historically, BT50 titers have been regarded as one such protec-
tive immunity marker. In this study, 3 subjects had baseline BT50 
titers of ≥200 and did not develop NV-related gastroenteritis, 
although one of them had an increase in antibody responses 
postchallenge. Elevated baseline titers were also associated with 
a lower risk of illness in a previous challenge study, particularly 
in placebo subjects [11, 29].
CONCLUSIONS
In summary, we have found that Lot 001-09NV is similar in vir-
ulence to previous passages of NV strain 8FIIa, with a similar 
safety profile, time to disease onset, and duration of illness in 
challenged subjects. All of these attributes make this lot a very 
useful challenge isolate to compare and standardize immune 
response levels and efficacy of various vaccine candidates. The 
large number of high virus titer stool samples collected here 
could serve as valuable sources of virus to pilot development of 
the human intestinal enteroid in vitro cell culture system, which 
allows for NV replication in an isolate-specific manner [30, 31].
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